Cited 12 times in
Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.date.accessioned | 2022-08-23T00:11:50Z | - |
dc.date.available | 2022-08-23T00:11:50Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189304 | - |
dc.description.abstract | Objective: Prevention of tuberculosis (TB) recurrence is an important issue in TB control. South Korea, a country with a high average income, has been challenged with an intermediate burden of TB. We aimed to estimate the TB recurrence rate after successful completion of the first anti-TB chemotherapy, and to identify the risk factors for the TB recurrence by focusing on co-morbidities and behavioral factors. Methods: This is a population-based cohort study using data from the National Health Insurance (NHI) database between 2002 and 2013. Newly diagnosed TB patients were identified using the classification of disease codes and prescription records. Final analytical subjects included people who successfully completed the first anti-TB chemotherapy. The primary outcome measure was recurrent TB 6-month after the first treatment completion. A set of associated risk factors, including demographic characteristics, co-morbidities, and health behavior factors were analyzed using Cox regression analysis. Results: Among 5,446 TB patients, 2,226 (40.1%) completed the first anti-TB treatment. During the follow-up period, 150 (6.7%) patients had TB recurrence, and the crude recurrent rate was 22.6 per 1000 person-years. The majority of recurrence cases (89%) occurred within the first 2-year period. The major findings show that participants who are male (adjusted HR (aHR) = 1.81, at a 95% CI, range: 1.11-2.94), older in age (aHR = 1.07, at a 95% CI, range: 1.00-1.14), have a lower income (aHR = 1.96, at a 95% CI, range: 1.10-3.48) and who are underweight (aHR = 1.92, at a 95% CI, range 1.15-3.20) were at higher risks for TB recurrence. Conclusion: People who have risk factors for recurrent TB need to improve treatment compliance through more effective TB management, and follow-up observation for one or two years after the treatment completion. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antitubercular Agents* / therapeutic use | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Tuberculosis* / drug therapy | - |
dc.subject.MESH | Tuberculosis* / epidemiology | - |
dc.subject.MESH | Tuberculosis* / prevention & control | - |
dc.title | Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hin Moi Youn | - |
dc.contributor.googleauthor | Moon-Kyung Shin | - |
dc.contributor.googleauthor | Dawoon Jeong | - |
dc.contributor.googleauthor | Hee-Jin Kim | - |
dc.contributor.googleauthor | Hongjo Choi | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.identifier.doi | 10.1371/journal.pone.0268290 | - |
dc.contributor.localId | A00057 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 35709199 | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.citation.volume | 17 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e0268290 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.17(6) : e0268290, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.